CytRx Q4 Revenues Up 11 Percent As Losses Swell 87 Percent | GenomeWeb

CytRx last week reported its financial results for the fourth quarter, posting revenues of $100,000, up slightly from $90,000 in the year-ago quarter. CytRx derives its revenues from licensing its Tranzfect DNA vaccine delivery technology, which it is no longer developing in-house.

The company's net loss in the period swelled 87 percent to $5.8 million, or $0.15 per share, from $3.1 million, or $0.09 per share, in the fourth quarter of 2003.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.